Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows
Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3
Grazoprevir/elbasvir shows high hepatitis C cure rate for people who inject drugs
People with HIV and HCV co-infection achieve high HCV cure rates with grazoprevir/elbasvir
Sofosbuvir/ledipasvir for 8 weeks cures most hard-to-treat hepatitis C patients in real-world study
Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co-infection
Strategies for hepatitis C ‘treatment as prevention’ must address the concerns of people who inject drugs
With EACS release, all international HIV treatment guidelines agree on when to start – for the first time since 2006
